sanofi
-
Financial
SOLID PERFORMANCE IN THE FIRST QUARTER OF 2016 WITH BUSINESS EPS UP 5.3% AT CONSTANT EXCHANGE RATES
PARIS, April 29, 2016 /PRNewswire/ — Sanofi (NYSE: SNY; EURONEXT: SAN) Q1 2016 Change Change (CER) Aggregate Group sales(1) €8,543m -1.9%…
Read More » -
Biologics
AASTROM COMPLETES ACQUISITION OF SANOFI’S CELL THERAPY AND REGENERATIVE MEDICINE BUSINESS
ANN ARBOR, Mich., June 2, 2014 (GLOBE NEWSWIRE) — Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular…
Read More » -
Aastrom Announces Definitive Agreement to Acquire Sanofi’s Cell Therapy and Regenerative Medicine Business
ANN ARBOR, Mich., April 21, 2014 (GLOBE NEWSWIRE) — Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular…
Read More » -
Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
PARIS, Aug. 29 /PRNewswire-FirstCall/ — Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has submitted a non-binding proposal to acquire Genzyme…
Read More »